STOCK TITAN

Biomea Fusion, Inc. Financials

BMEA
Source SEC Filings (10-K/10-Q) Updated Mar 24, 2026 Currency USD FYE March

This page shows Biomea Fusion, Inc. (BMEA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak
2/9

Biomea Fusion, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality
1.14x

For every $1 of reported earnings, Biomea Fusion, Inc. generates $1.14 in operating cash flow (-$70.4M OCF vs -$61.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk
-44.9x

Biomea Fusion, Inc. earns $-44.9 in operating income for every $1 of interest expense (-$83.5M vs $1.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
-$82.1M
YoY+42.3%

Biomea Fusion, Inc.'s EBITDA was -$82.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.3% from the prior year.

Net Income
-$61.8M
YoY+55.4%

Biomea Fusion, Inc. reported -$61.8M in net income in fiscal year 2025. This represents an increase of 55.4% from the prior year.

EPS (Diluted)
$-1.18
YoY+69.2%

Biomea Fusion, Inc. earned $-1.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 69.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow
-$70.7M
YoY+41.2%

Biomea Fusion, Inc. generated -$70.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 41.2% from the prior year.

Cash & Debt
$55.8M
YoY-4.2%
5Y CAGR-2.0%

Biomea Fusion, Inc. held $55.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
72M
YoY+99.1%
5Y CAGR+43.3%

Biomea Fusion, Inc. had 72M shares outstanding in fiscal year 2025. This represents an increase of 99.1% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
-209.1%
YoY+59.3pp
5Y CAGR-106.1pp

Biomea Fusion, Inc.'s ROE was -209.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 59.3 percentage points from the prior year.

Capital Allocation

R&D Spending
$62.0M
YoY-47.5%
5Y CAGR+76.0%

Biomea Fusion, Inc. invested $62.0M in research and development in fiscal year 2025. This represents a decrease of 47.5% from the prior year.

Share Buybacks
N/A
Capital Expenditures
$362K
YoY+0.0%
5Y CAGR+48.0%

Biomea Fusion, Inc. invested $362K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

BMEA Income Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses $14.4M-13.1% $16.6M-27.6% $22.9M-9.3% $25.2M-7.4% $27.2M-14.4% $31.8M-5.8% $33.8M+9.4% $30.9M
SG&A Expenses $4.2M-10.8% $4.7M-30.9% $6.8M+41.0% $4.8M-28.9% $6.8M-3.9% $7.1M-2.9% $7.3M+12.7% $6.5M
Operating Income -$20.8M+2.2% -$21.3M+28.4% -$29.7M+1.2% -$30.1M+11.6% -$34.0M+12.5% -$38.9M+5.3% -$41.1M-10.0% -$37.3M
Interest Expense $4.4M+720.5% $536K+19.1% $450K N/A $1.3M-22.8% $1.6M-18.8% $2.0M N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$16.4M+20.9% -$20.7M+29.1% -$29.3M+0.1% -$29.3M+10.6% -$32.8M+12.0% -$37.3M+4.6% -$39.1M-12.0% -$34.9M
EPS (Diluted) $-0.27+47.1% $-0.51+36.3% $-0.80+1.2% $-0.81+11.0% $-0.91+11.7% $-1.03+5.5% $-1.09-11.2% $-0.98

BMEA Balance Sheet

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Total Assets $55.2M-24.6% $73.2M+32.9% $55.1M-31.1% $79.9M-27.6% $110.4M-18.9% $136.2M-19.2% $168.5M-15.7% $199.9M
Current Assets $49.4M-23.5% $64.7M+44.7% $44.7M-34.6% $68.3M-27.0% $93.6M-19.5% $116.3M-21.2% $147.6M-17.6% $179.2M
Cash & Equivalents $46.6M-17.0% $56.2M+56.8% $35.9M-38.5% $58.3M-33.7% $88.0M-22.4% $113.3M-21.8% $144.9M-18.1% $176.9M
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $39.6M-13.3% $45.7M+73.5% $26.3M-7.2% $28.4M-17.7% $34.4M+6.9% $32.2M-2.9% $33.2M+8.1% $30.7M
Current Liabilities $15.6M-11.4% $17.6M-11.3% $19.8M-8.6% $21.7M-21.4% $27.6M+9.6% $25.2M-0.4% $25.3M+10.5% $22.9M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $15.6M-43.2% $27.5M-4.3% $28.7M-44.3% $51.6M-32.1% $76.0M-26.9% $103.9M-23.2% $135.3M-20.0% $169.2M
Retained Earnings -$453.7M-3.8% -$437.3M-5.0% -$416.5M-7.6% -$387.3M-8.2% -$357.9M-10.1% -$325.2M-12.9% -$287.9M-15.7% -$248.8M

BMEA Cash Flow Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Operating Cash Flow -$11.6M+39.9% -$19.2M+25.1% -$25.7M+14.5% -$30.0M-19.0% -$25.2M+22.7% -$32.6M-1.9% -$32.0M-40.3% -$22.8M
Capital Expenditures $0 $0 $0-100.0% $82K-55.9% $186K+215.3% $59K+68.6% $35K+337.5% $8K
Free Cash Flow -$11.6M+39.9% -$19.2M+25.1% -$25.7M+14.7% -$30.1M-18.4% -$25.4M+22.3% -$32.7M-2.0% -$32.1M-40.4% -$22.8M
Investing Cash Flow $0 $0 $0+100.0% -$82K+55.9% -$186K-215.3% -$59K-68.6% -$35K-337.5% -$8K
Financing Cash Flow $2.0M-95.0% $39.6M+1116.9% $3.3M+687.4% $413K+498.6% $69K-93.6% $1.1M+822.4% $116K-81.4% $622K
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

BMEA Financial Ratios

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity -105.0%-29.7pp -75.4%+26.4pp -101.8%-45.0pp -56.8%-13.7pp -43.2%-7.3pp -35.9%-7.0pp -28.9%-8.3pp -20.6%
Return on Assets -29.7%-1.4pp -28.3%+24.8pp -53.1%-16.5pp -36.7%-7.0pp -29.7%-2.3pp -27.4%-4.2pp -23.2%-5.7pp -17.4%
Current Ratio 3.18-0.5 3.68+1.4 2.25-0.9 3.15-0.2 3.39-1.2 4.62-1.2 5.84-2.0 7.84
Debt-to-Equity 2.53+0.9 1.66+0.7 0.92+0.4 0.55+0.1 0.45+0.1 0.31+0.1 0.25+0.1 0.18
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Similar Companies

Frequently Asked Questions

No, Biomea Fusion, Inc. (BMEA) reported a net income of -$61.8M in fiscal year 2025.

Biomea Fusion, Inc. (BMEA) reported diluted earnings per share of $-1.18 for fiscal year 2025. This represents a 69.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biomea Fusion, Inc. (BMEA) had EBITDA of -$82.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Biomea Fusion, Inc. (BMEA) has a return on equity of -209.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Biomea Fusion, Inc. (BMEA) generated -$70.7M in free cash flow during fiscal year 2025. This represents a 41.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Biomea Fusion, Inc. (BMEA) generated -$70.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Biomea Fusion, Inc. (BMEA) had $58.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Biomea Fusion, Inc. (BMEA) invested $362K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Biomea Fusion, Inc. (BMEA) invested $62.0M in research and development during fiscal year 2025.

Biomea Fusion, Inc. (BMEA) had 72M shares outstanding as of fiscal year 2025.

Biomea Fusion, Inc. (BMEA) had a current ratio of 5.23 as of fiscal year 2025, which is generally considered healthy.

Biomea Fusion, Inc. (BMEA) had a debt-to-equity ratio of 0.98 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Biomea Fusion, Inc. (BMEA) had a return on assets of -105.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Biomea Fusion, Inc. (BMEA) had $55.8M in cash against an annual operating cash burn of $70.4M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Biomea Fusion, Inc. (BMEA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Biomea Fusion, Inc. (BMEA) has an earnings quality ratio of 1.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Biomea Fusion, Inc. (BMEA) has an interest coverage ratio of -44.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top